SAMSUNG
23.2.2021 11:02:14 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN2, a new 50-megapixel (Mp) image sensor with large 1.4-micrometer (μm)-sized pixels. With enhancements to its predecessor, the ISOCELL GN1, the GN2 offers up to 100Mp imaging, improved auto-focusing through Dual Pixel Pro technology, powerful staggered HDR, and vivid results through Smart ISO Pro, regardless of the lighting environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005475/en/
“ISOCELL image sensors and its technologies have made vast improvements to deliver the quality and performance one would expect from top-tier prograde cameras,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “Our new ISOCELL GN2 features Dual Pixel Pro, an innovative all-direction auto-focusing solution that elevates the agility to capture moments as they unfold. Adding on Smart ISO Pro and a variety of advanced pixel technologies, pictures from GN2 are more true-to-life than ever.”
The 1/1.12-inch ISOCELL GN2 is a highly versatile image sensor when it comes to image resolutions. With 50 million 1.4μm-sized pixels on hand, the GN2 offers exceptionally detailed photographs in regular settings. In low-lit environments such as indoors, the sensor can simulate a larger 2.8μm-pixel with four-pixel-binning technology to absorb more light, delivering brighter and sharper images.
For those who appreciate more detail in photographs or are prone to post-processing such as image cropping, the GN2 offers an option to take pictures in 100Mp resolutions. In 100Mp mode, the GN2 meticulously re-arranges the color pixels using an intelligent re-mosaic algorithm, creating three individual layers of 50Mp frames in green, red and blue. These frames are then up-scaled and merged to produce a single ultra-high 100Mp resolution photograph.
The ISOCELL GN2 is Samsung’s first image sensor to offer Dual Pixel Pro, the company’s most advanced phase-detection auto-focus solution yet. By employing two photodiodes within every pixel of the image sensor, Dual Pixel Pro makes use of one hundred million phase detecting agents for ultra-fast auto-focusing. In addition, the solution also offers all-direction focusing by splitting the pixels not only vertically, as with Dual Pixel, but also diagonally. This diagonal cut allows the focusing agents to better recognize the top and bottom of the frame, allowing the sensor to get in focus quickly even when there are no pattern changes in a horizontal direction. Low-light focusing and tracking of moving objects are improved as well, as every pixel of the sensor works as focusing agents.
For taking pictures in mixed-light environments, such as sunsets or indoors with daylight coming through a window, the GN2 increases its dynamic range with a staggered-HDR feature, a time-multiplexed HDR technology that uses rolling shutters over the same pixel arrays to capture multiple frames in short, middle, and long exposures. By maximizing the dynamic range, staggered-HDR ensures rich detail and vivid color in highlights and dark shadows within the scene, making it an ideal solution for shooting high-contrast sights. Staggered-HDR is able to reduce the energy consumption of a sensor by up to 24-percent when compared to the predecessor’s real-time HDR mode, contributing to improved energy efficiency of the overall system.
The GN2 also comes with Smart ISO and Smart ISO Pro. Smart ISO intelligently sets the sensor’s conversion gain, allowing the picture to be taken using an optimal ISO; low ISO for brighter outdoors or high for dimmer indoors. Unlike Smart ISO, which uses readouts from a single ISO per picture, Smart ISO Pro, which uses an intra-scene dual conversion gain (iDCG) solution, takes readouts from both high and low ISO to instantly create high dynamic range images with less motion-artifacts. In addition, in extreme low-light, Smart ISO Pro quickly takes and processes multiple frames in high ISO, raising the light sensitivity close to one-million ISOs and taking mobile night photography to greater heights.
Camera experiences can be more fun and creative with the GN2, where precious moments can be captured more dramatically and everyday events can be turned into short videos. The GN2 supports full-HD videos at 480 frames-per-second (fps) or 4K at 120fps, enabling wider possibilities for mobile video-shooting.
Samsung ISOCELL GN2 is currently in mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005475/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
